{"id":652783,"date":"2023-05-24T15:46:01","date_gmt":"2023-05-24T15:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=652783"},"modified":"2023-05-24T15:46:01","modified_gmt":"2023-05-24T15:46:01","slug":"peripheral-artery-disease-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-20192032-key-companies-ixaka-ltd-formerly-rexgenero-hemostemix-inc-lisata-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/peripheral-artery-disease-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-20192032-key-companies-ixaka-ltd-formerly-rexgenero-hemostemix-inc-lisata-therapeutics_652783.html","title":{"rendered":"Peripheral Artery Disease Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies &#8211; Ixaka Ltd (formerly Rexgenero), Hemostemix Inc Lisata Therapeutics"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Peripheral Artery Disease Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - Ixaka Ltd (formerly Rexgenero), Hemostemix Inc Lisata Therapeutics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Peripheral Artery Disease Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - Ixaka Ltd (formerly Rexgenero), Hemostemix Inc Lisata Therapeutics\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s \u201cPeripheral Artery Disease Market Insights, Epidemiology and Market Forecast\u2013 2032\u201d report delivers an in-depth understanding of the Peripheral Artery Disease, historical and forecasted epidemiology as well as the Peripheral Artery Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Peripheral Artery Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Peripheral artery disease is a common manifestation of arterial stenosis of the lower and\/or upper extremities that reduces arterial flow. It is well known that Peripheral Artery Disease is associated with elevated morbidity and mortality with cardiovascular disease. In Peripheral Artery Disease, the legs or arms&mdash;usually the legs&mdash;do not receive enough blood flow to keep up with the demand, which may cause leg pain when walking (claudication) and other symptoms. Many people with Peripheral Artery Disease have no symptoms. The most common symptom of lower-extremity Peripheral Artery Disease is painful muscle cramping in the hips, thighs, or calves when walking, climbing stairs, or exercising. However, those who develop a painful ache in their legs when they walk usually disappear after a few minutes of rest. The medical term for this is &ldquo;intermittent claudication&rdquo;. The symptoms of Peripheral Artery Disease often develop slowly over time. If your symptoms develop quickly or get suddenly worse, it could be a sign of a serious problem requiring immediate treatment.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/15c8bebc01b66ea9736c51edfb06cbf5.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Peripheral Artery Disease Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">In 2022, the market size of Peripheral Artery Disease was highest in the US among the 7MM accounting for approximately USD 4 billion, and lowest in Spain with USD 130 million which is further expected to increase by 2032.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gender-specific diagnosed prevalent cases of Peripheral Artery Disease were higher in females (9 million cases) as compared to males (8 million) in 2022 in the 7MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to DelveInsight estimates, the US accounted for approximately 9 million cases, which was the highest diagnosed prevalent cases of Peripheral Artery Disease, followed by EU4 and the UK with 5 million cases, and Japan with 2 million cases in 2022. These cases are expected to increase in the US, EU4, the UK, and Japan by 2032<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Among the European countries, Germany had the highest diagnosed prevalent population of Peripheral Artery Disease (approximately 2 million cases), followed by Italy (approximately 1 million cases) in 2022. On the other hand, Spain (0.7 million cases) had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peripheral Artery Disease has been identified as a male-dominant disease; however, in our analysis, the number of women suffering was higher than males. In 2022, 49% of cases of Peripheral Artery Disease were in males, while 51% of cases were in Females in the 7MM.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-artery-disease-pad-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Peripheral Artery Disease Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Report Covers the Peripheral Artery Disease Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total Peripheral Artery Disease&nbsp; prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total Peripheral Artery Disease type-specific prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total Peripheral Artery Disease&nbsp; diagnosed cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total Peripheral Artery Disease&nbsp; treatable cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Peripheral Artery Disease Market Outlook&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The overall medical treatment for Peripheral Artery Disease is comprehensive and involves lowering cholesterol, antiplatelet therapy, anticoagulation, peripheral vasodilators, blood pressure control, exercise therapy, and quitting smoking. Numerous medications are available for managing claudication symptoms, secondary prevention of cardiovascular problems, and limb salvage therapy. Lifestyle change, medication management, endovascular therapies, and surgical interventions are different treatment options. Following this regime can lessen atherosclerosis-related systemic problems like stroke, myocardial infarction, and limb-related complications, including critical limb ischemia and amputation. Peripheral artery disease is undertreated compared to coronary artery disease. The current treatment strategies include endovascular revascularization, surgical revascularization, and primary amputation, and endovascular revascularization is a fundamental strategy to limb preservation. Other than surgical approaches, therapeutic angiogenesis can be achieved by gene and cell therapy. Collategene (HGF plasmid) is the only gene therapy that received approval in Japan. Apart from this, many cell therapies are under development.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-artery-disease-pad-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Companies Working in the Peripheral Artery Disease Market<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ixaka Ltd (formerly Rexgenero)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Hemostemix Inc<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lisata Therapeutics\/ Caladrius Biosciences<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Reven Pharmaceuticals, Inc<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Helixmith Co., Ltd<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Peripheral Artery Disease Therapies Covered and Analyzed in the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">ACP-01<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rivaroxaban&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ticagrelor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Clopidogrel<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Vonapanitase<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/peripheral-artery-disease-pad-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Companies and Emerging Therapies in the Peripheral Artery Disease Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peripheral Artery Disease &nbsp; Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Executive Summary of Peripheral Artery Disease&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peripheral Artery Disease Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peripheral Artery Disease Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peripheral Artery Disease Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peripheral Artery Disease Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peripheral Artery Disease Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/peripheral-artery-disease-pad-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Peripheral Artery Disease Market Outlook<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=peripheral-artery-disease-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-20192032-key-companies-ixaka-ltd-formerly-rexgenero-hemostemix-inc-lisata-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=peripheral-artery-disease-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-20192032-key-companies-ixaka-ltd-formerly-rexgenero-hemostemix-inc-lisata-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s \u201cPeripheral Artery Disease Market Insights, Epidemiology and Market Forecast\u2013 2032\u201d report delivers an in-depth understanding of the Peripheral Artery Disease, historical and forecasted epidemiology as well as the Peripheral Artery Disease market trends in the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/peripheral-artery-disease-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-20192032-key-companies-ixaka-ltd-formerly-rexgenero-hemostemix-inc-lisata-therapeutics_652783.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-652783","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/652783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=652783"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/652783\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=652783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=652783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=652783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}